Concepts (269)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Ultraviolet Therapy | 1 | 2020 | 1 | 0.770 |
Why?
|
| Keratitis | 1 | 2020 | 2 | 0.770 |
Why?
|
| Eye Infections, Bacterial | 1 | 2020 | 3 | 0.770 |
Why?
|
| Riboflavin | 1 | 2020 | 24 | 0.760 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 47 | 0.730 |
Why?
|
| Collagen | 1 | 2020 | 162 | 0.710 |
Why?
|
| Obesity | 6 | 2015 | 965 | 0.630 |
Why?
|
| Data Interpretation, Statistical | 1 | 2016 | 111 | 0.570 |
Why?
|
| Cluster Analysis | 1 | 2016 | 188 | 0.570 |
Why?
|
| Cardiovascular Diseases | 2 | 2015 | 628 | 0.560 |
Why?
|
| Risk Reduction Behavior | 3 | 2015 | 121 | 0.560 |
Why?
|
| Cyclooxygenase 2 | 2 | 2012 | 92 | 0.490 |
Why?
|
| Colorectal Neoplasms | 3 | 2019 | 413 | 0.470 |
Why?
|
| Adenoma | 2 | 2012 | 89 | 0.460 |
Why?
|
| Haplotypes | 2 | 2012 | 152 | 0.430 |
Why?
|
| Adenomatous Polyps | 1 | 2012 | 12 | 0.420 |
Why?
|
| Linkage Disequilibrium | 1 | 2012 | 58 | 0.420 |
Why?
|
| Polymorphism, Single Nucleotide | 4 | 2012 | 638 | 0.420 |
Why?
|
| Colonoscopy | 3 | 2019 | 98 | 0.400 |
Why?
|
| Colonic Polyps | 1 | 2012 | 67 | 0.390 |
Why?
|
| Male | 38 | 2022 | 18870 | 0.390 |
Why?
|
| Middle Aged | 28 | 2019 | 9642 | 0.380 |
Why?
|
| Humans | 47 | 2022 | 34853 | 0.380 |
Why?
|
| Carotid Artery, Common | 1 | 2009 | 9 | 0.370 |
Why?
|
| Patient Compliance | 3 | 2019 | 202 | 0.370 |
Why?
|
| Tunica Media | 1 | 2009 | 14 | 0.370 |
Why?
|
| Alcoholism | 5 | 2014 | 220 | 0.370 |
Why?
|
| Tunica Intima | 1 | 2009 | 21 | 0.370 |
Why?
|
| Brachial Artery | 1 | 2009 | 31 | 0.360 |
Why?
|
| Female | 35 | 2021 | 19873 | 0.350 |
Why?
|
| Blood Pressure | 3 | 2011 | 613 | 0.330 |
Why?
|
| Adult | 28 | 2021 | 11034 | 0.320 |
Why?
|
| Internship and Residency | 3 | 2015 | 121 | 0.320 |
Why?
|
| Research Subjects | 3 | 2021 | 31 | 0.310 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 195 | 0.300 |
Why?
|
| Regression Analysis | 5 | 2016 | 429 | 0.290 |
Why?
|
| Health Knowledge, Attitudes, Practice | 5 | 2019 | 790 | 0.280 |
Why?
|
| Proglumide | 2 | 2022 | 3 | 0.270 |
Why?
|
| Exercise | 4 | 2016 | 524 | 0.270 |
Why?
|
| District of Columbia | 7 | 2019 | 68 | 0.270 |
Why?
|
| Aged | 18 | 2019 | 6448 | 0.260 |
Why?
|
| Biomedical Research | 2 | 2022 | 371 | 0.260 |
Why?
|
| Body Mass Index | 5 | 2011 | 775 | 0.250 |
Why?
|
| Endoscopy | 2 | 2014 | 15 | 0.240 |
Why?
|
| Appointments and Schedules | 2 | 2014 | 19 | 0.230 |
Why?
|
| Genetic Testing | 2 | 2014 | 71 | 0.220 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2016 | 528 | 0.210 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 58 | 0.210 |
Why?
|
| Attitude of Health Personnel | 3 | 2019 | 186 | 0.210 |
Why?
|
| Hidradenitis Suppurativa | 1 | 2021 | 3 | 0.210 |
Why?
|
| Urinary Incontinence | 1 | 2021 | 15 | 0.200 |
Why?
|
| Hypertension | 3 | 2005 | 770 | 0.200 |
Why?
|
| Skin Pigmentation | 1 | 2021 | 18 | 0.200 |
Why?
|
| Cognition | 3 | 2016 | 373 | 0.200 |
Why?
|
| Aged, 80 and over | 9 | 2016 | 2333 | 0.200 |
Why?
|
| Risk Assessment | 3 | 2018 | 727 | 0.190 |
Why?
|
| Anemia, Sickle Cell | 3 | 2007 | 169 | 0.190 |
Why?
|
| Attitude to Health | 2 | 2014 | 311 | 0.190 |
Why?
|
| Outpatients | 3 | 2019 | 33 | 0.190 |
Why?
|
| Visual Acuity | 1 | 2020 | 98 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2020 | 233 | 0.170 |
Why?
|
| Ethanol | 2 | 2013 | 188 | 0.170 |
Why?
|
| Bacteria | 1 | 2022 | 245 | 0.170 |
Why?
|
| Patient Selection | 2 | 2021 | 154 | 0.170 |
Why?
|
| Life Style | 2 | 2015 | 288 | 0.160 |
Why?
|
| Specialties, Surgical | 1 | 2018 | 3 | 0.160 |
Why?
|
| Young Adult | 9 | 2015 | 4012 | 0.160 |
Why?
|
| Burnout, Professional | 1 | 2018 | 17 | 0.160 |
Why?
|
| United States | 9 | 2018 | 3894 | 0.160 |
Why?
|
| Stroke | 2 | 2011 | 274 | 0.150 |
Why?
|
| Mass Screening | 2 | 2019 | 427 | 0.150 |
Why?
|
| Referral and Consultation | 2 | 2015 | 110 | 0.150 |
Why?
|
| Normal Distribution | 1 | 2016 | 15 | 0.150 |
Why?
|
| Health Personnel | 1 | 2019 | 200 | 0.150 |
Why?
|
| Poisson Distribution | 1 | 2016 | 39 | 0.150 |
Why?
|
| Anti-Bacterial Agents | 1 | 2020 | 355 | 0.150 |
Why?
|
| Cohort Studies | 4 | 2015 | 1422 | 0.150 |
Why?
|
| Alcohol Drinking | 2 | 2013 | 490 | 0.150 |
Why?
|
| Early Detection of Cancer | 1 | 2019 | 292 | 0.150 |
Why?
|
| Substance-Related Disorders | 2 | 2015 | 685 | 0.140 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2016 | 58 | 0.140 |
Why?
|
| Apolipoprotein E4 | 1 | 2016 | 47 | 0.140 |
Why?
|
| China | 1 | 2016 | 178 | 0.140 |
Why?
|
| Alcohol Dehydrogenase | 2 | 2013 | 8 | 0.140 |
Why?
|
| Esophageal Neoplasms | 1 | 2016 | 124 | 0.130 |
Why?
|
| Psychotherapy, Brief | 1 | 2015 | 17 | 0.130 |
Why?
|
| Patient Dropouts | 1 | 2015 | 26 | 0.130 |
Why?
|
| Diet, Sodium-Restricted | 1 | 2015 | 11 | 0.130 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 254 | 0.130 |
Why?
|
| Caloric Restriction | 1 | 2015 | 29 | 0.130 |
Why?
|
| Cross-Sectional Studies | 5 | 2022 | 2561 | 0.130 |
Why?
|
| Case-Control Studies | 4 | 2012 | 1056 | 0.130 |
Why?
|
| Risk Factors | 5 | 2012 | 3414 | 0.120 |
Why?
|
| Phenotype | 3 | 2012 | 650 | 0.120 |
Why?
|
| Clinical Competence | 1 | 2015 | 124 | 0.120 |
Why?
|
| Cultural Competency | 1 | 2015 | 120 | 0.120 |
Why?
|
| Adolescent | 7 | 2015 | 5035 | 0.120 |
Why?
|
| Semicarbazides | 1 | 2013 | 2 | 0.120 |
Why?
|
| Algorithms | 1 | 2016 | 435 | 0.120 |
Why?
|
| Hydrazones | 1 | 2013 | 5 | 0.120 |
Why?
|
| Quality of Life | 1 | 2018 | 459 | 0.120 |
Why?
|
| Age Factors | 3 | 2018 | 1007 | 0.120 |
Why?
|
| Erythrocyte Membrane | 1 | 2013 | 20 | 0.120 |
Why?
|
| Nutrition Surveys | 2 | 2012 | 228 | 0.120 |
Why?
|
| Iron Chelating Agents | 1 | 2013 | 21 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2013 | 32 | 0.120 |
Why?
|
| Mortality | 2 | 2011 | 150 | 0.120 |
Why?
|
| Microfilament Proteins | 1 | 2013 | 64 | 0.120 |
Why?
|
| Gene Frequency | 2 | 2012 | 155 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2015 | 316 | 0.120 |
Why?
|
| Urban Population | 2 | 2012 | 318 | 0.110 |
Why?
|
| Antimalarials | 1 | 2013 | 48 | 0.110 |
Why?
|
| Job Application | 1 | 2012 | 3 | 0.110 |
Why?
|
| Personnel Selection | 1 | 2012 | 10 | 0.110 |
Why?
|
| Odds Ratio | 2 | 2012 | 517 | 0.110 |
Why?
|
| Ophthalmology | 1 | 2012 | 28 | 0.110 |
Why?
|
| Polymorphism, Genetic | 1 | 2013 | 165 | 0.110 |
Why?
|
| Education, Medical, Graduate | 1 | 2012 | 53 | 0.110 |
Why?
|
| Blood Proteins | 1 | 2012 | 65 | 0.110 |
Why?
|
| Career Choice | 1 | 2012 | 44 | 0.110 |
Why?
|
| Plasmodium falciparum | 1 | 2013 | 121 | 0.110 |
Why?
|
| Vitamins | 1 | 2012 | 91 | 0.110 |
Why?
|
| Introns | 1 | 2012 | 67 | 0.100 |
Why?
|
| Exons | 1 | 2012 | 80 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2012 | 67 | 0.100 |
Why?
|
| Cotinine | 1 | 2011 | 40 | 0.100 |
Why?
|
| Prospective Studies | 3 | 2021 | 1353 | 0.100 |
Why?
|
| Carrier Proteins | 1 | 2013 | 287 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 2 | 2012 | 484 | 0.100 |
Why?
|
| Multivariate Analysis | 2 | 2009 | 570 | 0.100 |
Why?
|
| Dilatation, Pathologic | 1 | 2009 | 9 | 0.090 |
Why?
|
| Cerebrovascular Circulation | 1 | 2009 | 71 | 0.090 |
Why?
|
| Statistics as Topic | 1 | 2009 | 111 | 0.090 |
Why?
|
| Vasodilation | 1 | 2009 | 65 | 0.090 |
Why?
|
| Ultrasonography | 1 | 2009 | 115 | 0.090 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2009 | 10 | 0.090 |
Why?
|
| Medical Staff, Hospital | 1 | 2009 | 13 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2009 | 34 | 0.090 |
Why?
|
| Osteoporosis | 1 | 2009 | 32 | 0.090 |
Why?
|
| Oxygen Consumption | 1 | 2009 | 98 | 0.090 |
Why?
|
| Logistic Models | 1 | 2012 | 894 | 0.080 |
Why?
|
| Circadian Rhythm | 1 | 2011 | 212 | 0.080 |
Why?
|
| Alcoholic Beverages | 1 | 2008 | 15 | 0.080 |
Why?
|
| Fractures, Bone | 1 | 2009 | 51 | 0.080 |
Why?
|
| Public Health | 1 | 2012 | 348 | 0.080 |
Why?
|
| Analysis of Variance | 1 | 2009 | 528 | 0.080 |
Why?
|
| Endothelium, Vascular | 1 | 2009 | 229 | 0.080 |
Why?
|
| Prevalence | 4 | 2019 | 1425 | 0.080 |
Why?
|
| Hypertension, Pulmonary | 1 | 2007 | 77 | 0.070 |
Why?
|
| Vitamin B 12 | 1 | 2006 | 19 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 198 | 0.070 |
Why?
|
| Obesity, Morbid | 1 | 2005 | 17 | 0.070 |
Why?
|
| HIV Infections | 1 | 2019 | 2207 | 0.070 |
Why?
|
| Alleles | 3 | 2016 | 284 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2012 | 592 | 0.070 |
Why?
|
| Smoking | 1 | 2011 | 903 | 0.060 |
Why?
|
| Linear Models | 1 | 2005 | 253 | 0.060 |
Why?
|
| Lipoprotein(a) | 1 | 2004 | 5 | 0.060 |
Why?
|
| Hyperlipidemias | 1 | 2004 | 35 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2015 | 1961 | 0.060 |
Why?
|
| Follow-Up Studies | 3 | 2012 | 964 | 0.060 |
Why?
|
| Receptors, Cholecystokinin | 1 | 2022 | 4 | 0.060 |
Why?
|
| Cholecystokinin | 1 | 2022 | 15 | 0.060 |
Why?
|
| Mixed Function Oxygenases | 1 | 2002 | 29 | 0.050 |
Why?
|
| Faculty | 1 | 2022 | 82 | 0.050 |
Why?
|
| Liver Cirrhosis | 1 | 2022 | 51 | 0.050 |
Why?
|
| Lipids | 1 | 2004 | 222 | 0.050 |
Why?
|
| Mental Recall | 2 | 2012 | 73 | 0.050 |
Why?
|
| Curriculum | 2 | 2015 | 237 | 0.050 |
Why?
|
| Neoplasms | 1 | 2011 | 1033 | 0.050 |
Why?
|
| Fibrosis | 1 | 2022 | 146 | 0.050 |
Why?
|
| Antigens, Viral | 1 | 2021 | 42 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 82 | 0.050 |
Why?
|
| Exercise Therapy | 2 | 2016 | 64 | 0.050 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2021 | 47 | 0.050 |
Why?
|
| Sex Factors | 2 | 2018 | 859 | 0.050 |
Why?
|
| Hemolysis | 2 | 2013 | 39 | 0.050 |
Why?
|
| Pilot Projects | 2 | 2016 | 628 | 0.050 |
Why?
|
| Molecular Dynamics Simulation | 1 | 2022 | 117 | 0.050 |
Why?
|
| Socioeconomic Factors | 2 | 2014 | 1003 | 0.050 |
Why?
|
| Sensitivity and Specificity | 1 | 2021 | 555 | 0.050 |
Why?
|
| Cathartics | 1 | 2019 | 6 | 0.050 |
Why?
|
| Liver | 1 | 2022 | 447 | 0.050 |
Why?
|
| Incidence | 2 | 2018 | 882 | 0.050 |
Why?
|
| Polyethylene Glycols | 1 | 2019 | 80 | 0.040 |
Why?
|
| Stereotyping | 1 | 2019 | 40 | 0.040 |
Why?
|
| Ambulatory Care | 1 | 2019 | 76 | 0.040 |
Why?
|
| Phylogeny | 1 | 2022 | 612 | 0.040 |
Why?
|
| Prejudice | 1 | 2019 | 101 | 0.040 |
Why?
|
| Diabetes Mellitus | 1 | 2004 | 465 | 0.040 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 2 | 2011 | 63 | 0.040 |
Why?
|
| Models, Molecular | 1 | 2022 | 751 | 0.040 |
Why?
|
| Prognosis | 2 | 2013 | 707 | 0.040 |
Why?
|
| Cholesterol, HDL | 2 | 2011 | 87 | 0.040 |
Why?
|
| Minority Groups | 1 | 2022 | 537 | 0.040 |
Why?
|
| Health Surveys | 1 | 2019 | 358 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2022 | 1530 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2022 | 1300 | 0.040 |
Why?
|
| Heterozygote | 1 | 2016 | 91 | 0.040 |
Why?
|
| Gene Expression Regulation | 1 | 2022 | 968 | 0.040 |
Why?
|
| Comorbidity | 2 | 2009 | 606 | 0.030 |
Why?
|
| Sample Size | 1 | 2015 | 28 | 0.030 |
Why?
|
| Anti-HIV Agents | 1 | 2019 | 394 | 0.030 |
Why?
|
| Diet, Reducing | 2 | 2005 | 22 | 0.030 |
Why?
|
| Research Personnel | 1 | 2015 | 133 | 0.030 |
Why?
|
| Hospitals | 1 | 2014 | 86 | 0.030 |
Why?
|
| Time Factors | 2 | 2012 | 1681 | 0.030 |
Why?
|
| Breath Tests | 1 | 2013 | 24 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 2013 | 48 | 0.030 |
Why?
|
| Siblings | 1 | 2013 | 16 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2002 | 794 | 0.030 |
Why?
|
| Communication | 1 | 2015 | 170 | 0.030 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 65 | 0.030 |
Why?
|
| Interprofessional Relations | 1 | 2012 | 48 | 0.030 |
Why?
|
| Educational Measurement | 1 | 2012 | 80 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 423 | 0.030 |
Why?
|
| Waist-Hip Ratio | 1 | 2011 | 32 | 0.030 |
Why?
|
| Obesity, Abdominal | 1 | 2011 | 26 | 0.030 |
Why?
|
| Seasons | 1 | 2012 | 112 | 0.030 |
Why?
|
| Chromatography, Liquid | 1 | 2012 | 140 | 0.030 |
Why?
|
| Cultural Diversity | 1 | 2012 | 158 | 0.030 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2012 | 173 | 0.020 |
Why?
|
| Mice | 1 | 2022 | 5668 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2013 | 859 | 0.020 |
Why?
|
| Perception | 1 | 2011 | 183 | 0.020 |
Why?
|
| Risk | 1 | 2010 | 256 | 0.020 |
Why?
|
| Women's Health | 1 | 2010 | 135 | 0.020 |
Why?
|
| Primary Health Care | 1 | 2012 | 283 | 0.020 |
Why?
|
| Causality | 1 | 2009 | 45 | 0.020 |
Why?
|
| Absorptiometry, Photon | 1 | 2009 | 73 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2008 | 50 | 0.020 |
Why?
|
| Awareness | 1 | 2009 | 59 | 0.020 |
Why?
|
| Cross-Over Studies | 1 | 2008 | 102 | 0.020 |
Why?
|
| Alcohol Withdrawal Delirium | 1 | 2008 | 2 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2008 | 58 | 0.020 |
Why?
|
| Child | 2 | 2007 | 2875 | 0.020 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2007 | 7 | 0.020 |
Why?
|
| Hematocrit | 1 | 2007 | 18 | 0.020 |
Why?
|
| Hemoglobin, Sickle | 1 | 2007 | 13 | 0.020 |
Why?
|
| Tricuspid Valve Insufficiency | 1 | 2007 | 13 | 0.020 |
Why?
|
| Heart Rate | 1 | 2009 | 248 | 0.020 |
Why?
|
| Bilirubin | 1 | 2007 | 17 | 0.020 |
Why?
|
| Blood Flow Velocity | 1 | 2007 | 63 | 0.020 |
Why?
|
| Echocardiography, Doppler | 1 | 2007 | 39 | 0.020 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 59 | 0.020 |
Why?
|
| Sex Distribution | 1 | 2008 | 212 | 0.020 |
Why?
|
| Emergency Service, Hospital | 1 | 2009 | 188 | 0.020 |
Why?
|
| Death, Sudden | 1 | 2006 | 1 | 0.020 |
Why?
|
| Autopsy | 1 | 2006 | 40 | 0.020 |
Why?
|
| Violence | 1 | 2008 | 126 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2010 | 1349 | 0.020 |
Why?
|
| Health Promotion | 1 | 2012 | 588 | 0.020 |
Why?
|
| Universities | 1 | 2009 | 363 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 154 | 0.020 |
Why?
|
| Heart Diseases | 1 | 2006 | 99 | 0.020 |
Why?
|
| Animals | 1 | 2022 | 14307 | 0.020 |
Why?
|
| Students | 1 | 2009 | 452 | 0.020 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2004 | 44 | 0.020 |
Why?
|
| Lipoproteins, LDL | 1 | 2004 | 61 | 0.010 |
Why?
|
| Triglycerides | 1 | 2004 | 129 | 0.010 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 77 | 0.010 |
Why?
|
| Cholesterol | 1 | 2004 | 194 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2002 | 22 | 0.010 |
Why?
|
| Nigeria | 1 | 2002 | 74 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 86 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2002 | 118 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2009 | 1802 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 932 | 0.010 |
Why?
|
| Genetic Variation | 1 | 2002 | 328 | 0.010 |
Why?
|